LIVN - LivaNova Continues To Be A Spring-Loaded Opportunity In Neuromodulation

• As per our first article, DTD remains incredibly attractive, even with conservative prevalence figures.
• The whole neuromodulation opportunity renders the company a potential growth engine.
• Three major trials are underway for three unmet medical needs which will rocket profile to one of high margins and cash generation.
• ASPs are high and products are fundamentally profitable with captive patients as this is quite last-line as a therapy.
• Company's valuation is modest despite likelihood of success in DTD, and prevalence of other VNS treatment areas.

For further details see: